# uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

> **NCT02964988** · PHASE2 · TERMINATED · sponsor: **Rigshospitalet, Denmark** · enrollment: 17 (actual)

## Conditions studied

- Prostate Cancer Metastatic
- Bone Metastases

## Interventions

- **DRUG:** Injection of PET tracer 68Ga-NOTA-AE105
- **DEVICE:** PET/CT

## Key facts

- **NCT ID:** NCT02964988
- **Lead sponsor:** Rigshospitalet, Denmark
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01
- **Primary completion:** 2019-10-11
- **Final completion:** 2019-10-11
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Recruitment issues and interim results
- **Last updated:** 2019-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02964988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02964988, "uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02964988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*